AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Invivyd Selects VBY329 as Potential Best-In-Class RSV Antibody Candidate.
ByAinvest
Monday, Nov 24, 2025 11:20 am ET1min read
Invivyd announces the selection of potential best-in-class RSV antibody candidate VBY329, targeting IND readiness in 2H 2026. VBY329 is designed to prevent RSV infections in newborns, infants, and children, and has shown higher potency and improved barrier to resistance compared to standard of care RSV medicines. Its antiviral potency is 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet